Vascular Access Choice and Outcomes in the Elderly and Very Elderly With End Stage Renal Disease in China
NCT ID: NCT02272374
Last Updated: 2014-10-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
500 participants
INTERVENTIONAL
2014-10-31
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Relationship Between the Flow of Arteriovenous Fistula and Cardiac Function in Haemodialysis Patients
NCT02747966
Hemodialysis in the Elderly (70yrs & Older)
NCT03065972
Clinical Values of Mature Fistulas in Hemodialysis
NCT04416971
Urgent-start Peritoneal Dialysis in ESRD Patients：A Multi-center Study
NCT02946528
Quality of Life on Peritoneal Dialysis Versus Hemodialysis in China
NCT02378350
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
e-AVF group
120 elderly with end stage renal disease will undergo AVF creation.
AVF creation
e-TCC group
120 elderly with end stage renal disease will undergo TCC placement.
TCC placement
e-AVG group
60 elderly with end stage renal disease will undergo AVG creation.
AVG creation
ve-AVF group
80 very elderly with end stage renal disease will undergo AVF creation.
AVF creation
ve-TCC group
80 very elderly with end stage renal disease will undergo TCC placement.
TCC placement
ve-AVG group
40 very elderly with end stage renal disease will undergo AVG creation.
AVG creation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AVF creation
TCC placement
AVG creation
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Estimated glomerular filtration rate (eGFR) \<20ml/min\*1.73m2
3. All study subjects agree to participate in the study and provide written informed consent.
Exclusion Criteria
2. Mental illness that makes the patients unable to complete the trial.
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First Affiliated Hospital of Zhejiang University
OTHER
Zhongda Hospital
OTHER
The First Affiliated Hospital of Zhengzhou University
OTHER
Sichuan Provincial People's Hospital
OTHER
The Second Affiliated Hospital of Dalian Medical University
OTHER
Beijing Haidian Hospital
OTHER
Shanghai Changzheng Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Changlin Mei
Professor, Director, Division of Nephrology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Changlin Mei, master
Role: PRINCIPAL_INVESTIGATOR
Division of Nephrology, Shanghai ChangZheng Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Changzheng Hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CZHKI-HDVA-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.